Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rifaquizinone + rabeprazole
- Development stage
- Unknown
- Lead developer
- TenNor Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**rifaquizinone + rabeprazole** is a combination drug consisting of rifaquizinone and rabeprazole. - Rabeprazole is a **proton pump inhibitor (PPI)** that acts by selectively and irreversibly inhibiting gastric H+/K+-ATPase in parietal cells, thereby reducing gastric acid secretion. It is primarily indicated for the treatment of gastroesophageal reflux disease (GERD), peptic ulcers, eradication of Helicobacter pylori in combination regimens, and pathologic hypersecretory conditions such as Zollinger-Ellison syndrome[1][3][4][6][7]. - The mechanism, developer, approved indications, and chemical details for **rifaquizinone** could not be verified in current references or databases, suggesting it may be investigational, have limited documentation, or be incorrectly named. - As a combination product, this therapy would likely leverage rabeprazole's acid suppression while adding effects from rifaquizinone based on its mechanism, should more details become available.
- Brand names
- rifaquizinone + rabeprazole
- Other names
- rifaquizinone + rabeprazole
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on rifaquizinone + rabeprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rifaquizinone + rabeprazole.